Clinical trials: Autoimmunity
Idiopathic Thrombocytopenia Purpura
A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability (BA) of two lots of E5501 40 mg tablets administered twice as single oral doses to healthy subjects.
- Trial name
- NCT01289509
- Testing
- E5501, Drug: E5501
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Chronic Inflammatory Disorder, Arthritis, Rheumatoid
A Relative Bioavailability and Food Effect Study of New Formulations
The purpose of this trial is to assess the effect of 3 formulations on the relative bioavailability of LY3009104. Participants will receive single dose of LY3009104 on 4 separate occasions with and without food.
- Trial name
- NCT01398475
- Testing
- LY3009104
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders
This is a randomized, double-blind, three-part, two-sequence per part, two-period, single-dose, cross-over study in healthy male volunteers to compare the PK, safety, and immunogenicity of MB04 and EU /US Enbrel®.
- Trial name
- MB04-A-01-23 (NCT06392074)
- Testing
- MB04, US License Enbrel, EU Source Enbrel
- Where
- Netherlands
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- mAbxience Research S.L.
IgA Nephropathy
A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
The goal of this clinical trial is to evaluate the effect of food (a high-fat, high-calorie meal) on the PK of a single oral dose of budesonide delayed release tablet in healthy participants.
- Trial name
- NCT07897240
- Testing
- Budesonide delayed release tablet
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Triastek, lnc.
Rheumatoid Arthritis &Amp; Other Inflammatory Polyarthropathies, Peripheral Spondyloarthritis
Automated Arthritis Detection Using Artificial Intelligence on Smartphone Photographs
The investigators are testing the ability of convolutional neural networks (CNNs), that is artificial intelligence, on smartphone photographs in detecting inflammatory arthritis.
- Conditions
- Rheumatoid Arthritis &Amp; Other Inflammatory Polyarthropathies, Peripheral Spondyloarthritis, Inflammatory Arthritis
- Trial name
- AISynovitis (NCT06715488)
- Testing
- AI assisted smartphone diagnosis
- Where
- 2 sites in India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Med2Measure
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
The main objective of this post-authorization safety study is to assess healthcare professionals' awareness, knowledge, and behavior related to receipt and reading of the Direct Healthcare Professional Communication and…
- Trial name
- ARAVA PASS (NCT06714461)
- Testing
- Leflunomide
- Where
- France
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
This study was intended to assess the safety, efficacy, and response to treatment using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) and to investigate a potential biomarker profile…
- Trial name
- NCT00504595
- Testing
- ACZ885 (investigational)
- Where
- 4 sites in Russia, Spain and 2 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novartis
Primary Immune Thrombocytopenia (ITP)
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous…
- Trial name
- NCT06929299
- Testing
- STSA-1301 subcutaneous injection
- Where
- 7 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu BioJeTay Biotechnology Co., Ltd.
Renal Impairments, IgA Nephropathy (IgAN)
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous…
- Trial name
- NCT07445906
- Testing
- RG002C0106
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Rheumatoid Arthritis, Healthy Volunteers
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
The purpose of this study is to investigate the drug interaction between fostamatinib and pioglitazone by comparing the safety, tolerability and plasma concentration of pioglitazone when administered alone and with fostamatinib…
- Conditions
- Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone
- Trial name
- NCT01309854
- Testing
- fostamatinib, pioglitazone
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Autoimmune Encephalitis
Phase 1 Study of ART5803 in Healthy Participants
The study is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT06575153
- Testing
- ART5803
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Arialys Therapeutics
Healthy Volunteers, Sjögren's Syndrome
A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
Primary Sjögren's syndrome (pSS) is a condition when the body's immune system attacks glands that produce fluids, such as the tear and saliva glands. This leads to dry eyes and a dry mouth.
- Trial name
- NCT06544642
- Testing
- ASP5502
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Systemic Lupus Erythematosus
Japanese phase1 Study of Belimumab (IV vs SC)
This study is an open-label, randomized, 2 parallel group, single dose study in healthy Japanese males to assess the pharmacokinetics and safety/tolerability of single intravenous administration and single subcutaneous…
- Trial name
- NCT01516450
- Testing
- GSK1550188 IV, GSK1550188 SC
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
IgA Nephropathy, Focal Segmental Glomerulosclerosis
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.
- Trial name
- NCT05942625
- Testing
- HS-10390 tablet
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Hansoh BioMedical R&D Company
Primary Immune Thrombocytopenia
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
A randomized, double-blind, placebo-controlled, single-ascending dose, phase Ia study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics, and immunogenicity of STSA-1301 Subcutaneous Injection in healthy…
- Trial name
- NCT06148389
- Testing
- STSA-1301 subcutaneous injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Type 1 Diabetes, Type 1 Diabetes Mellitus
Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D
Feasibility study to evaluate the safety and feasibility of Omnipod automated insulin delivery algorithms in individuals with type 1 diabetes.
- Conditions
- Type 1 Diabetes, Type 1 Diabetes Mellitus, Diabetes (DM)
- Trial name
- EVOLUTIONT1D (NCT07593625)
- Testing
- Omnipod M System, Omnipod S
- Where
- New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Insulet Corporation
Multiple Sclerosis
Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis
The aim of this study is the development of novel telemedical examination methods based on sensor-based gait analysis in patients with multiple sclerosis (MS).
- Trial name
- MSgoesHome (NCT04771858)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medical Valley Digital Health Application Center GmbH
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics